Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Artivion Inc (AORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: AORT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.71
1 Year Target Price $32.71
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.49% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 32.71 |
Price to earnings Ratio - | 1Y Target Price 32.71 | ||
Volume (30-day avg) 6 | Beta 1.62 | 52 Weeks Range 21.97 - 32.94 | Updated Date 07/10/2025 |
52 Weeks Range 21.97 - 32.94 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.49% | Operating Margin (TTM) -0.69% |
Management Effectiveness
Return on Assets (TTM) 1.54% | Return on Equity (TTM) -7.26% |
Valuation
Trailing PE - | Forward PE 102.04 | Enterprise Value 1836909793 | Price to Sales(TTM) 3.88 |
Enterprise Value 1836909793 | Price to Sales(TTM) 3.88 | ||
Enterprise Value to Revenue 4.71 | Enterprise Value to EBITDA 52.09 | Shares Outstanding 47037100 | Shares Floating 37726629 |
Shares Outstanding 47037100 | Shares Floating 37726629 | ||
Percent Insiders 5.01 | Percent Institutions 97.31 |
Upturn AI SWOT
Artivion Inc
Company Overview
History and Background
Artivion, Inc., formerly CryoLife, Inc., was founded in 1984. Initially focused on cryopreservation of human tissues, it expanded to develop and manufacture medical devices for cardiac and vascular surgeries. Significant milestones include FDA approvals for key products and acquisitions to broaden its product portfolio.
Core Business Areas
- Aortic: Develops, manufactures and distributes devices and implantable tissues used to repair or replace diseased or damaged aortic vessels. Products include aortic valves, aortic conduits, and stent grafts.
- Surgical Sealants: Offers BioGlue Surgical Adhesive, a surgical sealant used in various surgical procedures to achieve hemostasis and tissue sealing.
- Perfusion: Provides a range of perfusion products used during open-heart surgery, including oxygenators, blood filters, and other related devices.
- Cardiac Preservation: The company offers preservation services to preserve cardiovascular tissue.
Leadership and Structure
Artivion is led by President and CEO Pat Mackin. The company has a board of directors overseeing its operations. The organizational structure includes functional departments such as R&D, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- BioGlue Surgical Adhesive: A surgical sealant used in cardiovascular and general surgeries. Competitors include Baxter International (Tisseel), Johnson & Johnson (Evicel), and Medtronic (DuraSeal). Revenue from this product is significant, constituting a substantial portion of the surgical sealants segment revenue. Market share data fluctuates, but BioGlue holds a competitive position. Market share is unavailable.
- EACT (acellularized pulmonary homograft): Cryopreserved human tissues used for aortic and pulmonary valve replacement. Competitors include Medtronic, Edwards Lifesciences, and Abbott. Market share is unavailable.
- Aortic Stent Grafts: Used in endovascular repair of aortic aneurysms. Competitors include Medtronic, W. L. Gore & Associates, and Cook Medical. Market share is unavailable.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by an aging population, increasing prevalence of cardiovascular diseases, and technological advancements. Regulatory approvals and reimbursement policies significantly impact market access.
Positioning
Artivion is a player in the cardiovascular and surgical medical device market, with strengths in tissue-based products and surgical sealants. Its competitive advantage lies in its BioGlue product and established relationships with surgeons.
Total Addressable Market (TAM)
The global cardiovascular device market is estimated to be over $50 billion and growing. Artivion is positioned to capture a portion of this TAM through its product portfolio and strategic initiatives. TAM specifically for Artivion's product lines is unavailable.
Upturn SWOT Analysis
Strengths
- Proprietary products like BioGlue
- Established relationships with surgeons
- Strong brand reputation in certain product lines
- Focus on innovation in cardiovascular surgery
- Diverse product portfolio
Weaknesses
- Dependence on regulatory approvals
- Competition from larger medical device companies
- Potential product liability risks
- Manufacturing complexities associated with tissue-based products
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing products
- Acquiring complementary technologies or products
- Capitalizing on the growing demand for minimally invasive surgical procedures
Threats
- Changes in reimbursement policies
- Increased competition from new entrants
- Product recalls or safety concerns
- Economic downturn affecting hospital budgets
Competitors and Market Share
Key Competitors
- Edwards Lifesciences (EW)
- Medtronic (MDT)
- Baxter International (BAX)
- Johnson & Johnson (JNJ)
Competitive Landscape
Artivion faces competition from larger, more established medical device companies. Artivion's advantages lie in its specialized product offerings and focus on specific surgical procedures. Disadvantages include its smaller size and limited resources compared to its competitors.
Major Acquisitions
Jotec AG
- Year: 2017
- Acquisition Price (USD millions): 276
- Strategic Rationale: Expanded Artivion's presence in the European market and added a portfolio of aortic and peripheral vascular products.
Growth Trajectory and Initiatives
Historical Growth: Artivion's growth has been driven by organic sales growth and acquisitions. The company has focused on expanding its product portfolio and geographic reach.
Future Projections: Future growth projections depend on analyst estimates and company guidance. These projections would be based on factors such as new product launches, market trends, and competitive landscape.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand product offerings and investments in R&D to develop innovative medical devices.
Summary
Artivion is a player in the cardiovascular and surgical medical device market with a focus on aortic and surgical sealants. Strengths in niche products are being weighed against competition from larger companies. The company's focus on strategic acquisitions is helping to expand the company. Artivion needs to navigate regulatory landscape and competitive pressures carefully, while the company needs to innovate its product offering for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artivion Inc
Exchange NYSE | Headquaters Kennesaw, GA, United States | ||
IPO Launch date 1993-02-12 | Chairman, President & CEO Mr. James Patrick Mackin | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1600 | Website https://artivion.com |
Full time employees 1600 | Website https://artivion.com | ||
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.